Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment

Chimeric antigen receptor (CAR) immunotherapy is one of the most promising modern approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah<sup>&#174;</sup> and Yescarta<sup>&#174;</sup>, have been approved by the Food and Drug Administrati...

Full description

Bibliographic Details
Main Authors: Aleksei Titov, Aygul Valiullina, Ekaterina Zmievskaya, Ekaterina Zaikova, Alexey Petukhov, Regina Miftakhova, Emil Bulatov, Albert Rizvanov
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
chimeric antigen receptor
car t-cell therapy
tcr therapy
solid tumor
lymphoma
Online Access:https://www.mdpi.com/2072-6694/12/1/125

Internet

https://www.mdpi.com/2072-6694/12/1/125

Similar Items